In the groups of CLL patients categorized by the mutational status of IGHV genes and ZAP-70 expression, we found that in PBMC there were no differences in TLR7 expression in IGHV MUT and IGHV UM CLL patients (0.4805 vs. 0.583, p > 0.05) as well as in ZAP-70− and ZAP-70+ CLL patients (0.4935 vs. 0.532, p = 0.3738). The gene discussed is TLR7; the disease is B-cell chronic lymphocytic leukemia.